Liu G, Li C, Yang C, Liu S
Comput Struct Biotechnol J. 2025; 27:541-547.
PMID: 39981294
PMC: 11840938.
DOI: 10.1016/j.csbj.2025.01.015.
Kendall R, Martin A, Shah D, Shukla S, Compton C, Ismaila A
Int J Chron Obstruct Pulmon Dis. 2023; 18:1815-1825.
PMID: 37636901
PMC: 10454752.
DOI: 10.2147/COPD.S400707.
Groessl E, Tally S, Hillery N
Clinicoecon Outcomes Res. 2023; 15:239-250.
PMID: 37041933
PMC: 10083032.
DOI: 10.2147/CEOR.S400739.
Paly V, Vallejo-Aparicio L, Martin A, Luis Izquierdo J, Riesco J, Soler-Cataluna J
Int J Chron Obstruct Pulmon Dis. 2022; 17:3097-3109.
PMID: 36561129
PMC: 9766529.
DOI: 10.2147/COPD.S366765.
Halpin D, Kendall R, Shukla S, Martin A, Shah D, Midwinter D
Int J Chron Obstruct Pulmon Dis. 2022; 17:2745-2755.
PMID: 36317185
PMC: 9617516.
DOI: 10.2147/COPD.S370577.
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model.
Shukla S, Shah D, Martin A, Risebrough N, Kendall R, Vogelmeier C
Int J Chron Obstruct Pulmon Dis. 2021; 16:3105-3118.
PMID: 34916789
PMC: 8668403.
DOI: 10.2147/COPD.S331636.
Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK.
Fenwick E, Martin A, Schroeder M, Mealing S, Solanke O, Risebrough N
ERJ Open Res. 2021; 7(1).
PMID: 33778055
PMC: 7983252.
DOI: 10.1183/23120541.00480-2020.
Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective.
Schroeder M, Benjamin N, Atienza L, Biswas C, Martin A, Whalen J
Int J Chron Obstruct Pulmon Dis. 2020; 15:1621-1632.
PMID: 32764908
PMC: 7360413.
DOI: 10.2147/COPD.S240556.
Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.
Ismaila A, Risebrough N, Schroeder M, Shah D, Martin A, Goodall E
Int J Chron Obstruct Pulmon Dis. 2019; 14:2681-2695.
PMID: 31819401
PMC: 6890193.
DOI: 10.2147/COPD.S216072.
Personalized medicine for patients with COPD: where are we?.
Franssen F, Alter P, Bar N, Benedikter B, Iurato S, Maier D
Int J Chron Obstruct Pulmon Dis. 2019; 14:1465-1484.
PMID: 31371934
PMC: 6636434.
DOI: 10.2147/COPD.S175706.
Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
Driessen M, Whalen J, Buguth B, Vallejo-Aparicio L, Naya I, Asukai Y
Respir Res. 2018; 19(1):224.
PMID: 30458866
PMC: 6245710.
DOI: 10.1186/s12931-018-0916-7.
Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective.
Shah D, Driessen M, Risebrough N, Baker T, Naya I, Briggs A
Cost Eff Resour Alloc. 2018; 16:17.
PMID: 29773969
PMC: 5946544.
DOI: 10.1186/s12962-018-0101-3.
